Inno-lipa HPV genotyping extra
Inno-lipa HPV genotyping extra has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Nov 16, 2026: “Comparative performance of three HPV DNA detection assays for cervical cancer screening in Algeria”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1 papers on inno-lipa HPV genotyping extra
At a glance
The findings reach people, from one lab or study. 1 lab.
“Among the 94 specimens tested by both INNO-LiPA and Cobas, HR-HPV was detected in 54.3% and 29.8%, respectively”
None of its findings points the other way.
- 1 lab
- Humans1
What did studies of inno-lipa HPV genotyping extra find?
1Studies of inno-lipa HPV genotyping extra measured one outcome, high-risk HPV detection.
High-risk HPV detection
upin humans1
1 study
High-risk HPV detection
upin humans1
Inno-lipa HPV genotyping extra is linked with higher high-risk HPV detection in humans (Compared with Cobas 4800 HPV) (54.3% versus 29.8%).
“Among the 94 specimens tested by both INNO-LiPA and Cobas, HR-HPV was detected in 54.3% and 29.8%, respectively”
HumansCompared with Cobas 4800 HPVcervixfemalesn = 94
Comparative performance of three HPV DNA detection assays for cervical cancer screening in Algeria
African journal of reproductive health
What is inno-lipa HPV genotyping extra linked with?
1Studies link inno-lipa HPV genotyping extra with Diagnostic sensitivity and specificity.
Diagnostic sensitivity and specificity
mixedin humans1
1 study
Diagnostic sensitivity and specificity
mixedin humans1
Inno-lipa HPV genotyping extra is associated with diagnostic sensitivity and specificity in humans (Compared with Cobas using the study-defined composite reference classification) (Sensitivity 93% versus 71%; specificity 62% versus 88%).
“INNO-LiPA showed higher sensitivity (93%) but lower specificity (62%) than Cobas (71% and 88%, respectively).”
HumansCompared with Cobas using the study-defined composite reference classificationcervixfemales
Comparative performance of three HPV DNA detection assays for cervical cancer screening in Algeria
African journal of reproductive health